New Research Coverage Highlights Array BioPharma, Impax Laboratories, Baxter International, Timken Steel, National Health Investors, and Donaldson — Consolidated Revenues, Company Growth, and Expectations for 2018

Loading...
Loading...

NEW YORK, Dec. 05, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Array BioPharma Inc. ARRY, Impax Laboratories, Inc. IPXL, Baxter International Inc. BAX, Timken Steel Corporation TMST, National Health Investors, Inc. NHI, and Donaldson Company, Inc. DCI, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

ARRY DOWNLOAD: http://Fundamental-Markets.com/register/?so=ARRY
IPXL DOWNLOAD: http://Fundamental-Markets.com/register/?so=IPXL
BAX DOWNLOAD: http://Fundamental-Markets.com/register/?so=BAX
TMST DOWNLOAD: http://Fundamental-Markets.com/register/?so=TMST
NHI DOWNLOAD: http://Fundamental-Markets.com/register/?so=NHI
DCI DOWNLOAD: http://Fundamental-Markets.com/register/?so=DCI

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Array BioPharma Inc. ARRY, Impax Laboratories, Inc. IPXL, Baxter International Inc. BAX, Timken Steel Corporation TMST, National Health Investors, Inc. NHI, and Donaldson Company, Inc. DCI on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed December 1st, 2017. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

Loading...
Loading...

Array BioPharma Inc. (ARRY) REPORT OVERVIEW

Array BioPharma's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Array BioPharma reported revenue of $29.75MM vs $39.27MM (down 24.25%) and basic earnings per share -$0.22 vs -$0.20. For the twelve months ended June 30th, 2017 vs June 30th, 2016, Array BioPharma reported revenue of $150.85MM vs $137.88MM (up 9.41%) and basic earnings per share -$0.72 vs -$0.65. Array BioPharma is expected to report earnings on February 8th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$0.14. The estimated EPS forecast for the next fiscal year is -$0.58 and is expected to report on August 8th, 2018.

To read the full Array BioPharma Inc. (ARRY) report, download it here: http://Fundamental-Markets.com/register/?so=ARRY

-----------------------------------------

Impax Laboratories, Inc. (IPXL) REPORT OVERVIEW

Impax Laboratories' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Impax Laboratories reported revenue of $206.39MM vs $227.91MM (down 9.44%) and basic earnings per share -$0.69 vs -$2.51. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Impax Laboratories reported revenue of $824.43MM vs $860.47MM (down 4.19%) and basic earnings per share -$6.63 vs $0.56. Impax Laboratories is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.16. The estimated EPS forecast for the next fiscal year is $0.97 and is expected to report on March 7th, 2018.

To read the full Impax Laboratories, Inc. (IPXL) report, download it here: http://Fundamental-Markets.com/register/?so=IPXL

-----------------------------------------

Baxter International Inc. (BAX) REPORT OVERVIEW

Baxter International's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Baxter International reported revenue of $2,707.00MM vs $2,558.00MM (up 5.82%) and basic earnings per share $0.46 vs $0.24 (up 91.67%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, Baxter International reported revenue of $10,163.00MM vs $9,968.00MM (up 1.96%) and basic earnings per share $9.09 vs $1.78 (up 410.67%). Baxter International is expected to report earnings on February 7th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $0.57. The estimated EPS forecast for the next fiscal year is $2.71 and is expected to report on February 7th, 2018.

To read the full Baxter International Inc. (BAX) report, download it here: http://Fundamental-Markets.com/register/?so=BAX

-----------------------------------------

Timken Steel Corporation (TMST) REPORT OVERVIEW

Timken Steel's Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, Timken Steel reported revenue of $339.10MM vs $213.80MM (up 58.61%) and basic earnings per share -$0.13 vs -$0.50. For the twelve months ended December 31st, 2016 vs December 31st, 2015, Timken Steel reported revenue of $869.50MM vs $1,106.20MM (down 21.40%) and basic earnings per share -$2.39 vs -$1.01. Timken Steel is expected to report earnings on February 15th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was -$1.52. The estimated EPS forecast for the next fiscal year is $0.92 and is expected to report on February 15th, 2018.

To read the full Timken Steel Corporation (TMST) report, download it here: http://Fundamental-Markets.com/register/?so=TMST

-----------------------------------------

National Health Investors, Inc. (NHI) REPORT OVERVIEW

National Health Investors' Recent Financial Performance

For the three months ended September 30th, 2017 vs September 30th, 2016, National Health Investors reported revenue of $71.35MM vs $63.25MM (up 12.81%) and basic earnings per share $0.95 vs $0.84 (up 13.10%). For the twelve months ended December 31st, 2016 vs December 31st, 2015, National Health Investors reported revenue of $248.50MM vs $228.99MM (up 8.52%) and basic earnings per share $3.88 vs $3.96 (down 2.02%). National Health Investors is expected to report earnings on February 16th, 2018. The report will be for the fiscal period ending December 31st, 2017. The reported EPS for the same quarter last year was $1.27. The estimated EPS forecast for the next fiscal year is $5.46 and is expected to report on February 16th, 2018.

To read the full National Health Investors, Inc. (NHI) report, download it here: http://Fundamental-Markets.com/register/?so=NHI

-----------------------------------------

Donaldson Company, Inc. (DCI) REPORT OVERVIEW

Donaldson's Recent Financial Performance

For the three months ended July 31st, 2017 vs July 31st, 2016, Donaldson reported revenue of $660.10MM vs $593.80MM (up 11.17%) and basic earnings per share $0.53 vs $0.45 (up 17.78%). For the twelve months ended July 31st, 2017 vs July 31st, 2016, Donaldson reported revenue of $2,371.90MM vs $2,220.30MM (up 6.83%) and basic earnings per share $1.76 vs $1.43 (up 23.08%). Donaldson is expected to report earnings on March 7th, 2018. The report will be for the fiscal period ending January 31st, 2018. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $2.10 and is expected to report on September 6th, 2018.

To read the full Donaldson Company, Inc. (DCI) report, download it here: http://Fundamental-Markets.com/register/?so=DCI

-----------------------------------------

ABOUT FUNDAMENTAL MARKETS

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com 

© 2017 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.  

Loading...
Loading...
Posted In: Press Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...